[G15-07] Ibrutinib (new therapeutic indication) - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Last updated 20.10.2015
Project no.:
G15-07
Commission:
Commission awarded on 01.08.2015 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Withdrawn commission
Department/Division:
Health Economics
Topic:
Cancer
Note:
The commission was withdrawn by the Federal Joint Committee in agreement with IQWiG on 15.10.2015. G-BA documents on this decision
| Project no. | Title | Status |
|---|---|---|
| G14-11 | Ibrutinib - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A16-60 | Ibrutinib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-39 | Ibrutinib (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-04 | Ibrutinib - Benefit assessment according to §35a Social Code Book V | Commission completed |